IN8bio Q3 net loss $7.2M; cash $12.9M; clinical progress on gamma-delta T cell trials

IN8BIO, INC.

2023-Q3 EPS reported -$0.79

Net loss $7.2M ($0.23/sh) vs $7.4M ($0.34/sh) in Q3 2022; R&D $3.8M, G&A $3.4M.
Cash $12.9M at Sep 30, 2023, down from $17.0M at Jun 30, 2023.
Phase 1 INB-100 dose escalation completed; ASH data presentation Dec 11, 2023.
Phase 2 INB-400 in newly diagnosed GBM enrollment initiated; SNO poster Nov 17.
Phase 1 INB-200 updated data at SNO Nov 17; Cohort 3 enrollment ongoing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IN8BIO, INC. reported the three months ended September 30, 2023 results: net income Net loss of $7.2 million, or $0.23 per basic and diluted common share, EPS $0.23 per basic and diluted common share.

Period: the three months ended September 30, 2023
Net income: Net loss of $7.2 million, or $0.23 per basic and diluted common share
EPS: $0.23 per basic and diluted common share
Result: reported results

Exact text from the filing

The Company reported a net loss of $7.2 million, or $0.23 per basic and diluted common share, for the three months ended September 30, 2023

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

IN8BIO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-061992

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.